Paul D. Maroni, MD, Author at Grand Rounds in Urology

Paul D. Maroni, MD

University of Colorado, Denver

Aurora, Colorado

Paul D. Maroni, MD, is the Program Leader of the Urologic Oncology Program at the University of Colorado in Aurora. He graduated from the University of Virginia in 1996 and from the University of Illinois College of Medicine in 2000. In 2006, Dr. Maroni completed his residency at the University of Colorado at Denver and Health Sciences Center prior to receiving fellowship training in Urologic Oncology at Indiana University. He returned to the University of Colorado as a faculty member in 2007. Dr. Maroni provides care to patients at the Tony Grampsas Urologic Cancer Care Clinic - Anschutz Medical Campus, where he specializes in robotic surgery for prostate or kidney cancer. As of 2020, he had performed over 1000 robotic prostate removals. He also performs minimally invasive HoLEP procedures for patients with enlarged prostates.
Dr. Maroni has published widely on the topics of prostate and testicular cancer. His specific clinical and academic interests include minimally invasive therapies for prostate cancer, robotic surgery, and surgery for metastatic testicular cancer. He is an investigator for numerous clinical trials about a wide range of subjects, from diagnostic tools to complementary medicines to immunotherapy for localized prostate cancer. Dr. Maroni’s other research interests center in quality of life outcomes for patients with prostate cancer and testicular cancer. His ultimate goal is that patients who survive cancer return to a better-than-normal state and use their cancer diagnoses to engage in healthy, life-enhancing behaviors.

Talks by Paul D. Maroni, MD

Horizons of Diagnosis and Treatment with PSMA PET MRI

Posted by Paul D. Maroni, MD | Aug 2024

Paul D. Maroni, MD, discusses advancements in prostate cancer imaging, emphasizing PSMA PET/MRI. Recent trends show that most new patients arrive with MRIs or even PSMA PET/CT scans; however, access to PSMA PET/MRI remains limited due to approval issues.

In this 10-minute presentation, Dr. Maroni highlights findings from the Primary Trial, which combines MRI and PSMA PET to screen for clinically significant cancers. This fusion is highly specific in identifying high-risk patients, potentially bypassing biopsies in specific cases. Moreover, studies in Canada are investigating PSMA PET/MRI’s role in guiding treatments like SBRT and focal ablation, indicating its potential as a prognostic and predictive biomarker.

Maroni suggests PSMA PET/MRI could serve in initial workups, replacing PET/CT, and aiding in post-treatment follow-up to assess cure or recurrence. There’s also interest in advancing fusion technology to overlay PSMA PET with pre-existing MRIs, optimizing cost-effectiveness and patient care by minimizing additional radiation.

Optimizing Physical Wellbeing for Providers

Posted by Paul D. Maroni, MD | Apr 2024

Paul D. Maroni, MD, shares personal insights on maintaining health and well-being while balancing the demands of a medical career. This 20-minute discussion centers on ten key strategies to avoid burnout and improve overall wellness.

Maroni begins by categorizing health pillars into five main areas: sleep, nutrition, fitness, emotional and stress management, and the role of medications and supplements. He gives advice on maintaining a healthy work-life balance, adopting behavior changes, and seeking regular medical checkups. Dr. Maroni encourages colleagues to be proactive in their health, set small achievable goals, and approach wellness with the same dedication they apply to patient care.

Salvage Lymph Node Dissection for Prostate Cancer

Posted by Paul D. Maroni, MD | Jul 2019

Paul D. Maroni, MD, argues that salvage pelvic lymph node dissection is feasible, safe, and may be efficacious in the treatment of oligometastatic prostate cancer. He reviews data suggesting that this method can optimize locoregional control, limit the risk of distant progression, avoid the necessity for immediate androgen deprivation therapy (ADT), and improve cancer-specific survival.